Professor Henrik Grönberg is awarded the Swedish Cancer Foundation's Cancer Researcher of the Year 2022 for his research that enables early detection of prostate cancer. Henrik Grönberg’s research has led to the test Stockholm3.
The Cancer Foundation's research committee, chaired by former chairman of the Nobel Committee, Klas Kärre, gave the following justification:
“For world-leading research on prostate cancer. For methods of detecting prostate cancer at an early stage, but also to avoid unnecessary examinations, as well as to identify the patients who need to be treated immediately. All this contributes to more individualized treatment, increased chance of cure and high quality of life.”
“I am very happy and honored to get this award. Prostate cancer is the most common and deadliest form of cancer for men in Sweden. Unfortunately, 2,300 men in Sweden alone still die every year. We now have the tools to introduce general screening, which would significantly reduce mortality from the disease,” said Professor Grönberg.
“The award from the Swedish Cancer Foundation shows the great value that Stockholm3 adds through earlier detection of prostate cancer and by simultaneously reducing unnecessary treatments. This award follows last summer's award for best abstract in oncology at the European Association of Urology. We are very proud of these national and international awards, which are also important milestones in our work to establish Stockholm3 globally and radically improve the precision in prostate cancer diagnostics,” said David Rosén, CEO of A3P Biomedical.
Henrik Grönberg is a professor of cancer epidemiology at Karolinska Institutet and a senior physician. Henrik is a co-founder of A3P Biomedical and a leading expert in prostate cancer. Since 2005, Henrik has been a professor at Karolinska Institutet, where he leads a research group with 35 researchers focused on prostate cancer. He is also responsible for the Prostate Cancer Center at Capio S:t Göran’s Hospital in Stockholm.